234 related articles for article (PubMed ID: 28321905)
1. Differential increments of basal glucagon-like-1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter-individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes.
Liang H; Xu W; Zhou L; Yang W; Weng J
Diabet Med; 2017 Jul; 34(7):987-992. PubMed ID: 28321905
[TBL] [Abstract][Full Text] [Related]
2. SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients.
He R; Zhang D; Lu W; Zheng T; Wan L; Liu F; Jia W
Diabetes Res Clin Pract; 2015 Jul; 109(1):57-63. PubMed ID: 26004431
[TBL] [Abstract][Full Text] [Related]
3. Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients.
Raj GM; Mathaiyan J; Wyawahare M; Priyadarshini R
Drug Metab Pers Ther; 2018 Dec; 33(4):175-185. PubMed ID: 30433870
[TBL] [Abstract][Full Text] [Related]
4. Association of the SLC47A1 Gene Variant With Responses to Metformin Monotherapy in Drug-naive Patients With Type 2 Diabetes.
Kim H; Bae S; Yoon HY; Yee J; Gwak HS
J Clin Endocrinol Metab; 2022 Aug; 107(9):2684-2690. PubMed ID: 35639991
[TBL] [Abstract][Full Text] [Related]
5. Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.
Pérez-Gómez N; Fernández-Ortega MD; Elizari-Roncal M; Santos-Mazo E; la Maza-Pereg L; Calvo S; Alcaraz R; Sanz-Solas A; Vinuesa R; Saiz-Rodríguez M
Pharmacogenomics; 2023 Aug; 24(12):651-663. PubMed ID: 37610884
[TBL] [Abstract][Full Text] [Related]
6. Genomic editing of metformin efficacy-associated genetic variants in SLC47A1 does not alter SLC47A1 expression.
Kalamajski S; Huang M; Dalla-Riva J; Keller M; Dawed AY; Hansson O; Pearson ER; ; Mulder H; Franks PW
Hum Mol Genet; 2022 Feb; 31(4):491-498. PubMed ID: 34505146
[TBL] [Abstract][Full Text] [Related]
7. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study.
Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH
J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients.
Hou W; Zhang D; Lu W; Zheng T; Wan L; Li Q; Bao Y; Liu F; Jia W
Mol Diagn Ther; 2015 Feb; 19(1):25-33. PubMed ID: 25573751
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes.
Tkáč I; Klimčáková L; Javorský M; Fabianová M; Schroner Z; Hermanová H; Babjaková E; Tkáčová R
Diabetes Obes Metab; 2013 Feb; 15(2):189-91. PubMed ID: 22882994
[TBL] [Abstract][Full Text] [Related]
10. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
Otsuka Y; Yamaguchi S; Furukawa A; Kosuda M; Nakazaki M; Ishihara H
Endocr J; 2015; 62(2):133-43. PubMed ID: 25328079
[TBL] [Abstract][Full Text] [Related]
11. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia).
Yu Pan C; Han P; Liu X; Yan S; Feng P; Zhou Z; Lv X; Tian H; Jin Kui Y; Su B; Shang S; Niemoeller E
Diabetes Metab Res Rev; 2014 Nov; 30(8):726-35. PubMed ID: 24639432
[TBL] [Abstract][Full Text] [Related]
12. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Diabetes; 2009 Mar; 58(3):745-9. PubMed ID: 19228809
[TBL] [Abstract][Full Text] [Related]
13. The influence of SLC22A3 rs543159 and rs1317652 genetic variants on metformin therapeutic efficacy in newly diagnosed patients with type 2 diabetes mellitus: 25 weeks follow-up study.
Taheri R; Kazerouni F; Mirfakhraei R; Kalbasi S; Shahrokhi SZ; Rahimipour A
Gene; 2022 May; 823():146382. PubMed ID: 35240257
[TBL] [Abstract][Full Text] [Related]
14. Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment.
Wang N; Zhang JP; Xing XY; Yang ZJ; Zhang B; Wang X; Yang WY
J Diabetes; 2017 Aug; 9(8):728-737. PubMed ID: 27717194
[TBL] [Abstract][Full Text] [Related]
15. A Protocol for the Study of Polymorphisms and Response to Metformin in Patients with Type 2 Diabetes in Trinidad.
Clement Y; Singh S; Motilal S; Maharaj R; Nunez-Smith M
Ethn Dis; 2020; 30(Suppl 1):211-216. PubMed ID: 32269463
[TBL] [Abstract][Full Text] [Related]
16. Association of
Chen P; Cao Y; Chen S; Liu Z; Chen S; Guo Y
Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289808
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels.
Zhang JP; Wang N; Xing XY; Yang ZJ; Wang X; Yang WY
J Diabetes; 2016 Jul; 8(4):559-67. PubMed ID: 26331290
[TBL] [Abstract][Full Text] [Related]
18. The role of genetic factors and kidney and liver function in glycemic control in type 2 diabetes patients on long-term metformin and sulphonylurea cotreatment.
Klen J; Goričar K; Janež A; Dolžan V
Biomed Res Int; 2014; 2014():934729. PubMed ID: 25025077
[TBL] [Abstract][Full Text] [Related]
19. Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany.
Khunti K; Godec TR; Medina J; Garcia-Alvarez L; Hiller J; Gomes MB; Cid-Ruzafa J; Charbonnel B; Fenici P; Hammar N; Hashigami K; Kosiborod M; Nicolucci A; Shestakova MV; Ji L; Pocock S
Diabetes Obes Metab; 2018 Feb; 20(2):389-399. PubMed ID: 28817227
[TBL] [Abstract][Full Text] [Related]
20. The influence of metformin transporter gene SLC22A1 and SLC47A1 variants on steady-state pharmacokinetics and glycemic response.
Ningrum VDA; Sadewa AH; Ikawati Z; Yuliwulandari R; Ikhsan MR; Fajriyah R
PLoS One; 2022; 17(7):e0271410. PubMed ID: 35905099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
